Nanotherapeutics Acquires Late Stage Clinical Program for Alzheimer's Treatment

December 16, 2009 - Nanotherapeutics, Inc., a privately held biopharmaceutical company, announced that it has acquired in bankruptcy proceedings two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 from EPIX Pharmaceuticals, Inc. Ramoplanin - an oral antibiotic for the treatment of Clostridium difficileassociated disease (CDAD) - is entering Phase 3 trials. PRX-3140 - an orally-bioavailable Alzheimer’s treatment - is in Phase 2 clinical studies. Nanotherapeutics also acquired the U.S. and foreign patent estates covering each clinical program... [PDF] Nanotherapeutics' Press Release -

EPIX Pharmaceuticals : 2008 Alzheimer's Association International Conference on Alzheimer's Disease

Jul 24, 2008 - EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it is scheduled to make two presentations at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease in Chicago...


...In May 2008, EPIX announced the initiation of a Phase 2b proof-of-concept program for PRX-03140 that consists of two clinical trials - a six-month trial evaluating PRX-03140 in combination with donepezil and a three-month trial studying PRX-03140 as monotherapy. PRX-03140 is part of EPIX's strategic collaboration with GlaxoSmithKline, which is conducted through GSK's Center of Excellence for External Drug Discovery (CEEDD)... EPIX Pharmaceuticals' Press Release -

EPIX Pharmaceuticals : Phase 2a Alzheimer's Data at Keystone Symposia

March 25, 2008--EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that Tom Megerian, M.D., Ph.D, executive director, clinical research of EPIX, is scheduled to present an oral presentation entitled "Results of a Phase 2A Study of a Novel 5HT4 Agonist for the Treatment of Alzheimer's Disease" at the Keystone Symposia Alzheimer's Disease Meeting in Keystone, Colorado on Friday, March 28, 2008 at 8:00 a.m. MDT.

EPIX previously announced the compelling results of a Phase 2a clinical trial of PRX-03140 as a single agent and in combination with Aricept(R) in patients with mild Alzheimer's disease. Dr. Megerian's presentation will focus on these previously reported data.

PRX-03140 is part of EPIX's strategic partnership with GlaxoSmithKline... EPIX's Press Release -

EPIX Pharmaceuticals , Second Discovery Program in Collaboration with GlaxoSmithKline

Nov. 5, 2007-... In December 2006, EPIX and GSK announced a worldwide multi-target strategic collaboration to discover, develop and market novel medicines targeting four G-protein coupled receptors (GPCRs) for the treatment of a variety of diseases, including EPIX's novel 5-HT4 partial agonist program, PRX-03140, which is in early-stage clinical development for the treatment of Alzheimer's disease... EPIX 's Press Release -